Free tool
FAERS Monitor: Orgovyx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214621 or its brand name (Orgovyx, Relugolix). Reports on generic versions are filed under their own applications.
Reports
24,260
Serious
6,066
25% of reports
Hospitalization
2,257
Death reported
1,187
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hot flush7,658
- fatigue5,907
- therapy interrupted3,381
- incorrect dose administered2,129
- asthenia1,977
- arthralgia1,592
- diarrhoea1,554
- dizziness1,344
- product dose omission issue1,338
- constipation1,049
- death1,005
- weight increased894
- pain867
- insomnia853
- myalgia824
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 472 |
| 2022 | 2,334 |
| 2023 | 2,979 |
| 2024 | 5,774 |
| 2025 | 10,315 |
| 2026 | 2,376 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,899 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hot flushSignal | 7,658 | 97.9 | 96.0 | 662,429 |
| therapy interruptedSignal | 3,381 | 43.0 | 41.6 | 132,559 |
| incorrect dose administeredSignal | 2,129 | 8.2 | 7.8 | 13,374 |
| fatigueSignal | 5,907 | 6.6 | 6.5 | 29,041 |
| astheniaSignal | 1,977 | 4.6 | 4.4 | 5,595 |
| myalgiaSignal | 824 | 4.2 | 3.9 | 2,026 |
| constipationSignal | 1,049 | 4.2 | 3.9 | 2,554 |
| product dose omission issueSignal | 1,338 | 4.0 | 3.8 | 2,983 |
| weight increasedSignal | 894 | 3.5 | 3.3 | 1,581 |
| arthralgiaSignal | 1,592 | 3.3 | 3.2 | 2,633 |
| insomniaSignal | 853 | 2.8 | 2.6 | 981 |
| dizzinessSignal | 1,344 | 2.3 | 2.2 | 1,052 |
| diarrhoeaSignal | 1,554 | 2.1 | 2.0 | 908 |
| pain | 867 | 1.2 | 1.1 | 36 |
| death | 1,005 | 1.0 | 1.0 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.